Literature DB >> 15475932

Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2.

Panayiotis A Kyzas1, Dimitrios Stefanou, Anna Batistatou, Niki J Agnantis.   

Abstract

Vascular endothelial growth factor is a peptide with well-defined actions on the vasculature and fundamental role in tumor angiogenesis. Its action in vascular endothelium is exerted in a paracrine manner. The immunohistochemical expression of this protein by cancer cells in head and neck squamous cell carcinoma was correlated with increased tumor aggressiveness and poor survival in previous studies. In the past years, an increasing amount of studies demonstrated potential autocrine action of vascular endothelial growth factor in various neoplasms. However, the existence and the impact of such autocrine action in head and neck cancer have not been demonstrated yet. In this retrospective study, we evaluated the expression of vascular endothelial growth factor and its receptors in neoplastic cells, in a cohort of patients with head and neck squamous cell carcinoma, and compared this expression with tumor aggressiveness, clinicopathologic parameters and outcome. High expression of vascular endothelial growth factor was strongly correlated with high expression of vascular endothelial growth factor receptor-2 (but not vascular endothelial growth factor receptor-1) on the cancer cells (P<0.001). The co-overexpression of both the protein and vascular endothelial growth factor receptor-2 was associated with higher tumor proliferation rate (P<0.001). The above co-overexpression also correlated with worse survival (log rank P<0.05) in patients with oral-larynx squamous cell carcinoma. Our results suggest that an autocrine vascular endothelial growth factor loop, mediated via vascular endothelial growth factor receptor-2, probably exists in head and neck squamous cell carcinoma. These observations support the hypothesis that the use of vascular endothelial growth factor receptor-2 inhibitors as adjuvant antiangiogenic therapy might have beneficial effects for these patients, by disrupting both paracrine (endothelial-dependent) and autocrine actions of vascular endothelial growth factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15475932     DOI: 10.1038/modpathol.3800295

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.

Authors:  Meng Tong; Brandon Lloyd; Ping Pei; Susan R Mallery
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

2.  VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density.

Authors:  Carla Ariotti; Vivian Petersen Wagner; Gabriela Salvadori; Vinicius Coelho Carrard; Marco Antônio Trevizani Martins; Joao Julio da Cunha Filho; Luise Meurer; Manoela Domingues Martins
Journal:  Tumour Biol       Date:  2015-04-21

Review 3.  Emerging drugs to treat squamous cell carcinomas of the head and neck.

Authors:  Christopher Fung; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

4.  Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent.

Authors:  J T Lucas; B P Salimath; M G Slomiany; S A Rosenzweig
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

Review 5.  Promising new molecular targeted therapies in head and neck cancer.

Authors:  Kelly Dorsey; Mark Agulnik
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

Review 6.  Transcriptional targeting of tumor endothelial cells for gene therapy.

Authors:  Zhihong Dong; Jacques E Nör
Journal:  Adv Drug Deliv Rev       Date:  2009-04-23       Impact factor: 15.470

7.  Promising newer molecular-targeted therapies in head and neck cancer.

Authors:  Lili X Wang; Mark Agulnik
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Phase II study of sunitinib malate in head and neck squamous cell carcinoma.

Authors:  Nicholas W Choong; Mark Kozloff; David Taber; H Shawn Hu; James Wade; Percy Ivy; Theodore G Karrison; Allison Dekker; Everett E Vokes; Ezra E W Cohen
Journal:  Invest New Drugs       Date:  2009-08-04       Impact factor: 3.850

9.  Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?

Authors:  Daniel Drescher; Markus Moehler; Ines Gockel; Kirsten Frerichs; Annett Müller; Friedrich Dünschede; Thomas Borschitz; Stefan Biesterfeld; Martin Holtmann; Thomas Wehler; Andreas Teufel; Kerstin Herzer; Thomas Fischer; Martin R Berger; Theodor Junginger; Peter R Galle; Carl C Schimanski
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

10.  Immunotherapy of head and neck cancer: current and future considerations.

Authors:  Alexander D Rapidis; Gregory T Wolf
Journal:  J Oncol       Date:  2009-08-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.